https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-01347-7 https://www.ncbi.nlm.nih.gov/pubmed/32907566?dopt=Abstract Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator. Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator. Respir […]
Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients
https://www.globenewswire.com/news-release/2020/09/08/2089903/0/en/Synairgen-announces-positive-data-from-interim-analysis-of-SNG001-trial-in-COPD-patients.html Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients
Therapeutic effects of black seed oil supplementation on chronic obstructive pulmonary disease patients: A randomized controlled double blind clinical trial
https://www.cell.com/heliyon/fulltext/S2405-8440(20)31554-1 https://www.ncbi.nlm.nih.gov/pubmed/32904114?dopt=Abstract Therapeutic effects of black seed oil supplementation on chronic obstructive pulmonary disease patients: A randomized controlled double blind clinical trial. Therapeutic effects of black seed oil supplementation on chronic obstructive pulmonary disease patients: A randomized controlled double blind clinical trial. Heliyon. 2020 Aug;6(8):e04711 Authors: Al-Azzawi MA, AboZaid MMN, Ibrahem RAL, Sakr MA Abstract […]
Drug development for severe respiratory diseases supported with $3.9 million grant: New drug candidate targets asthma, COPD, other progressive lung diseases
Drug development for severe respiratory diseases supported with $3.9 million grant Drug development for severe respiratory diseases supported with $3.9 million grant New drug candidate targets asthma, COPD, other progressive lung diseases
Biomarkers in Chronic Obstructive Pulmonary Disease: The Gateway to Precision Medicine
https://www.sciencedirect.com/science/article/abs/pii/S0272523120300344?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/32800193?dopt=Abstract Biomarkers in Chronic Obstructive Pulmonary Disease: The Gateway to Precision Medicine. Biomarkers in Chronic Obstructive Pulmonary Disease: The Gateway to Precision Medicine. Clin Chest Med. 2020 Sep;41(3):383-394 Authors: Milne S, Sin DD Abstract Chronic obstructive pulmonary disease (COPD) is a highly heterogeneous disease with limited adequate treatments. Biomarkers-which may relate to disease susceptibility, […]
The Potential Role and Regulatory Mechanisms of MUC5AC in Chronic Obstructive Pulmonary Disease
https://www.preprints.org/manuscript/202008.0260/v1 The Potential Role and Regulatory Mechanisms of MUC5AC in Chronic Obstructive Pulmonary Disease Jingyuan Li and Zuguang Ye * Version 1 : Received: 10 August 2020 / Approved: 11 August 2020 / Online: 11 August 2020 (09:20:57 CEST)
Impaired lnc-IL7R modulatory mechanism of Toll-like receptors is associated with an exacerbator phenotype of chronic obstructive pulmonary disease.
https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.202000632R https://www.ncbi.nlm.nih.gov/pubmed/32780913?dopt=Abstract Impaired lnc-IL7R modulatory mechanism of Toll-like receptors is associated with an exacerbator phenotype of chronic obstructive pulmonary disease. Impaired lnc-IL7R modulatory mechanism of Toll-like receptors is associated with an exacerbator phenotype of chronic obstructive pulmonary disease. FASEB J. 2020 Aug 11;: Authors: Wu SM, Feng PH, Chuang HC, Ho SC, Fan Chung K, […]
Preventive and therapeutic effectiveness of Sanfu acupoint herbal patching for chronic obstructive pulmonary disease at stable stages: a systematic review and meta-analysis
https://kns.cnki.net/kcms/detail/detail.aspx?doi=10.19852/j.cnki.jtcm.2020.04.003 https://www.ncbi.nlm.nih.gov/pubmed/32744021?dopt=Abstract Preventive and therapeutic effectiveness of Sanfu acupoint herbal patching for chronic obstructive pulmonary disease at stable stages: a systematic review and Meta-analysis. Related Articles Preventive and therapeutic effectiveness of Sanfu acupoint herbal patching for chronic obstructive pulmonary disease at stable stages: a systematic review and Meta-analysis. J Tradit Chin Med. 2020 Aug;40(4):530-549 Authors: […]
Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy
https://www.resmedjournal.com/article/S0954-6111(20)30238-9/fulltext https://www.ncbi.nlm.nih.gov/pubmed/32777683?dopt=Abstract Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy. Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy. Respir Med. 2020 Jul 30;171:106098 Authors: Mallah H, Ball S, Sekhon J, Parmar K, Nugent K Abstract Platelets are essential mediators of inflammation […]
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
https://clinicaltrials.gov/ct2/show/NCT04072887?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients Condition : Pulmonary Disease, Chronic Obstructive Interventions : Drug: QBW251; Drug: Placebo Sponsor : Novartis Pharmaceuticals Not yet recruiting NCT04072887 Wed, 28 Aug 2019 12:00:00 EDT
Therapeutic Effects of SRT2104 on Lung Injury in Rats with Emphysema via Reduction of Type II Alveolar Epithelial Cell Senescence
https://www.tandfonline.com/doi/abs/10.1080/15412555.2020.1797657?journalCode=icop20 https://www.ncbi.nlm.nih.gov/pubmed/32722945?dopt=Abstract Therapeutic Effects of SRT2104 on Lung Injury in Rats with Emphysema via Reduction of Type II Alveolar Epithelial Cell Senescence. Related Articles Therapeutic Effects of SRT2104 on Lung Injury in Rats with Emphysema via Reduction of Type II Alveolar Epithelial Cell Senescence. COPD. 2020 Jul 28;:1-8 Authors: Gu C, Zhang Q, Ni D, […]
AstraZeneca Wins FDA Approval for COPD Treatment
https://www.biospace.com/article/fda-approves-astrazeneca-s-copd-treatment-breztri-aerosphere/ AstraZeneca Wins FDA Approval for COPD Treatment
Difference in the metabolic characteristics of chronic obstructive pulmonary disease patients and healthy adults
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386978/ https://www.ncbi.nlm.nih.gov/pubmed/32791715?dopt=Abstract Difference in the metabolic characteristics of chronic obstructive pulmonary disease patients and healthy adults. Related Articles Difference in the metabolic characteristics of chronic obstructive pulmonary disease patients and healthy adults. Medicine (Baltimore). 2020 Jul 24;99(30):e21302 Authors: Jiang Y, Hu H, Li X, He X, Shao X, Lou J, Zhang Y, Wu Y, Fang […]
ADAM15 deficiency increased pulmonary inflammation in mice and is strongly linked to the pathogenesis of COPD
https://www.nature.com/articles/s41385-020-0325-3 https://www.ncbi.nlm.nih.gov/pubmed/32690871?dopt=Abstract A disintegrin and metalloproteinase domain-15 deficiency leads to exaggerated cigarette smoke-induced chronic obstructive pulmonary disease (COPD)-like disease in mice. ADAM15 deficiency increased pulmonary inflammation in mice and is strongly linked to the pathogenesis of COPD Related Articles A disintegrin and metalloproteinase domain-15 deficiency leads to exaggerated cigarette smoke-induced chronic obstructive pulmonary disease (COPD)-like […]
Fecal microbial transplantation (FMT) and a high fiber diet (HFD) attenuates emphysema development by suppressing inflammation and apoptosis
https://www.nature.com/articles/s12276-020-0469-y https://www.ncbi.nlm.nih.gov/pubmed/32681029?dopt=Abstract Fecal microbial transplantation and a high fiber diet attenuates emphysema development by suppressing inflammation and apoptosis. Related Articles Fecal microbial transplantation and a high fiber diet attenuates emphysema development by suppressing inflammation and apoptosis. Exp Mol Med. 2020 Jul 17;: Authors: Jang YO, Lee SH, Choi JJ, Kim DH, Choi JM, Kang MJ, […]
Verona Pharma Raises $200 Million to support Phase 3 ENHANCE clinical program in COPD
https://www.globenewswire.com/news-release/2020/07/17/2063777/0/en/Verona-Pharma-Raises-200-Million-in-Oversubscribed-Private-Placement-and-Subscription.html Verona Pharma Raises $200 Million to support Phase 3 ENHANCE clinical program in COPD
ADAM15 expression is increased in lung CD8+ T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction
https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-01446-5 https://www.ncbi.nlm.nih.gov/pubmed/32677970?dopt=Abstract ADAM15 expression is increased in lung CD8+ T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction. Related Articles ADAM15 expression is increased in lung CD8+ T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction. Respir […]
Mediated Drug Release from Nano-Vehicles by Black Phosphorus Quantum Dots for Efficient Therapy of Chronic Obstructive Pulmonary Disease
https://onlinelibrary.wiley.com/doi/abs/10.1002/anie.202008379 https://www.ncbi.nlm.nih.gov/pubmed/32666703?dopt=Abstract Mediated Drug Release from Nano-Vehicles by Black Phosphorus Quantum Dots for Efficient Therapy of Chronic Obstructive Pulmonary Disease. Related Articles Mediated Drug Release from Nano-Vehicles by Black Phosphorus Quantum Dots for Efficient Therapy of Chronic Obstructive Pulmonary Disease. Angew Chem Int Ed Engl. 2020 Jul 15;: Authors: Li Z, Luo G, Hu WP, […]
Vitamin B12 Supplementation and NT-proBNP Levels in COPD Patients: A Secondary Analysis of a Randomized and Controlled Study
https://www.frontiersin.org/articles/10.3389/fnins.2020.00740/full https://www.ncbi.nlm.nih.gov/pubmed/32760247?dopt=Abstract Vitamin B12 Supplementation and NT-proBNP Levels in COPD Patients: A Secondary Analysis of a Randomized and Controlled Study in Rehabilitation. Related Articles Vitamin B12 Supplementation and NT-proBNP Levels in COPD Patients: A Secondary Analysis of a Randomized and Controlled Study in Rehabilitation. Front Neurosci. 2020;14:740 Authors: Paulin FV, Goelzer LS, Müller PT Abstract […]
PR1P as a novel therapeutic agent for the treatment of emphysema or other lung diseases characterized by VEGF signaling dysregulation
https://www.atsjournals.org/doi/10.1165/rcmb.2019-0434OC https://www.ncbi.nlm.nih.gov/pubmed/32663413?dopt=Abstract PR1P Stabilizes VEGF and Upregulates its Signaling to Reduce Elastase Induced Murine Emphysema. Related Articles PR1P Stabilizes VEGF and Upregulates its Signaling to Reduce Elastase Induced Murine Emphysema. Am J Respir Cell Mol Biol. 2020 Jul 14;: Authors: Adini A, Wu H, Dao DT, Ko VH, Yu LJ, Pan A, Puder M, Mitiku […]
Fiber Metabolism in Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT04459156?type=Intr https://clinicaltrials.gov/ct2/show/NCT04459156?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Fiber Metabolism in Chronic Obstructive Pulmonary Disease Condition : Chronic Obstructive Pulmonary Disease Interventions : Dietary Supplement: Fiber Inulin; Dietary Supplement: Placebo Maltodextrin Sponsor : Texas A&M University Recruiting NCT04459156 Tue, 07 Jul 2020 12:00:00 EDT
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
https://www.nejm.org/doi/full/10.1056/NEJMoa1916046 Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab (SAR231893) in Patients With Moderate to Severe COPD With Type 2 Inflammation
https://clinicaltrials.gov/ct2/show/NCT04456673?type=Intr https://clinicaltrials.gov/ct2/show/NCT04456673?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation Condition : Chronic Obstructive Pulmonary Disease Interventions : Drug: Dupilumab SAR231893; Drug: Inhaled Corticosteroid; Drug: Inhaled Long-Acting Beta Agonist; Drug: Inhaled Long-Acting Muscarinic Antagonist; Drug: Placebo Sponsors : Sanofi; Regeneron Pharmaceuticals Recruiting NCT04456673 Thu, 02 Jul 2020 12:00:00 EDT
Long non-coding RNA NNT-AS1 regulates proliferation, apoptosis, inflammation and airway remodeling of chronic obstructive pulmonary disease via targeting miR-582-5p/FBXO11 axis
https://www.sciencedirect.com/science/article/pii/S0753332220305187?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/32768929?dopt=Abstract Long non-coding RNA NNT-AS1 regulates proliferation, apoptosis, inflammation and airway remodeling of chronic obstructive pulmonary disease via targeting miR-582-5p/FBXO11 axis. Related Articles Long non-coding RNA NNT-AS1 regulates proliferation, apoptosis, inflammation and airway remodeling of chronic obstructive pulmonary disease via targeting miR-582-5p/FBXO11 axis. Biomed Pharmacother. 2020 Jul 02;129:110326 Authors: Mei J, Zhang Y, Lu […]
Twice-daily Budesonide/Glycopyrrolate/Formoterol Significantly Lowered Exacerbations in Patients with Moderate or Severe COPD
https://www.mdmag.com/conference-coverage/ats-2020/budesonide-lama-laba-reduces-annual-copd-exacerbation Budesonide Plus LAMA/LABA Significantly Reduces Annual COPD Exacerbation Twice-daily budesonide/glycopyrrolate/formoterol significantly lowered exacerbations in patients with moderate or severe chronic obstructive pulmonary disease (COPD) versus a pair of double therapy inhalers, according to new findings.
The Role of Toll-Like Receptors 2 (TLR2) and 4 (TLR4) in the Pathogenesis of Chronic Obstructive Pulmonary Disease
https://www.dovepress.com/the-role-of-toll-like-receptors-2-and-4-in-the-pathogenesis-of-chronic-peer-reviewed-fulltext-article-COPD https://www.ncbi.nlm.nih.gov/pubmed/32606656?dopt=Abstract The Role of Toll-Like Receptors 2 and 4 in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Related Articles The Role of Toll-Like Receptors 2 and 4 in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1481-1493 Authors: Sidletskaya K, Vitkina T, Denisenko Y Abstract Currently, chronic obstructive pulmonary […]
Lung Denervation System Named FDA Breakthrough Device
Lung Denervation System Named FDA Breakthrough Device Lung Denervation System Named FDA Breakthrough Device
The Adjunctive Effect of Intravenous Magnesium Sulfate in Acute Exacerbation of COPD
https://www.ncbi.nlm.nih.gov/pubmed/32542879?dopt=Abstract The Adjunctive Effect of Intravenous Magnesium Sulfate in Acute Exacerbation of COPD: A Randomized Controlled Clinical Trial. The Adjunctive Effect of Intravenous Magnesium Sulfate in Acute Exacerbation of COPD: A Randomized Controlled Clinical Trial. Acad Emerg Med. 2020 Jun 15;: Authors: Vafadar Moradi E, Pishbin E, Habibzadeh SR, Talebi Doluee M, Soltanifar A Abstract […]
CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial
https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-01401-4 https://www.ncbi.nlm.nih.gov/pubmed/32532258?dopt=Abstract CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. Related Articles CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. Respir Res. 2020 Jun 12;21(1):149 Authors: Lazaar AL, Miller BE, Donald AC, Keeley T, Ambery C, Russell […]
NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD
https://www.nature.com/articles/s42255-020-0215-8 https://www.ncbi.nlm.nih.gov/pubmed/32694733?dopt=Abstract NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Related Articles NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nat Metab. 2020 Jun;2(6):532-546 Authors: Seimetz M, Sommer N, Bednorz M, Pak O, Veith C, Hadzic S, Gredic M, Parajuli N, Kojonazarov B, Kraut S, Wilhelm J, […]
Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device
https://www.nuvaira.com/nuvaira-announces-fda-breakthrough-designation-for-airflow-3-pivotal-trial-device/ Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device
Effects of compound Caoshi silkworm granules (CCSGs) on stable COPD patients and their relationship with gut microbiota
https://journals.lww.com/md-journal/FullText/2020/05290/Effects_of_compound_Caoshi_silkworm_granules_on.118.aspx https://www.ncbi.nlm.nih.gov/pubmed/32481473?dopt=Abstract Effects of compound Caoshi silkworm granules on stable COPD patients and their relationship with gut microbiota: A randomized controlled trial. Related Articles Effects of compound Caoshi silkworm granules on stable COPD patients and their relationship with gut microbiota: A randomized controlled trial. Medicine (Baltimore). 2020 May 29;99(22):e20511 Authors: Hu Y, Shi Q, Ying […]
A New Report Confirms Significant Benefits in Patient Reported Outcomes at One Year Following the Non-Surgical Zephyr Valve Procedure for COPD/Emphysema
https://www.businesswire.com/news/home/20200512005517/en/New-Report-Confirms-Significant-Benefits-Patient-Reported A New Report Confirms Significant Benefits in Patient Reported Outcomes at One Year Following the Non-Surgical Zephyr Valve Procedure for COPD/Emphysema
The Relevance of Targeting Treatment to Small Airways in Asthma and COPD: the newest technological therapeutic advances
https://www.ncbi.nlm.nih.gov/pubmed/32209703?dopt=Abstract http://rc.rcjournal.com/content/early/2020/03/24/respcare.07237 The Relevance of Targeting Treatment to Small Airways in Asthma and COPD. Related Articles The Relevance of Targeting Treatment to Small Airways in Asthma and COPD. Respir Care. 2020 Mar 24;: Authors: Santus P, Radovanovic D, Pecchiari M, Ferrando M, Tursi F, Patella V, Braido F Abstract COPD and asthma have different risk […]
Hesperidin alleviated inflammation and oxidative stress responses in COPD mice, associated with SIRT1/PGC-1α/NF-κB signaling axis: a new direction for COPD treatment
https://www.tandfonline.com/doi/abs/10.1080/10799893.2020.1738483?journalCode=irst20 https://www.ncbi.nlm.nih.gov/pubmed/32164488?dopt=Abstract Function of hesperidin alleviating inflammation and oxidative stress responses in COPD mice might be related to SIRT1/PGC-1α/NF-κB signaling axis. Hesperidin alleviated inflammation and oxidative stress responses in COPD mice, associated with SIRT1/PGC-1α/NF-κB signaling axis: a new direction for COPD treatment J Recept Signal Transduct Res. 2020 Mar 13;:1-7 Authors: Wang S, He N, […]
Lung Volume Reduction Coil Treatment Enables Recovery in Severe COPD Cases
https://www.ajmc.com/newsroom/lung-volume-reduction-coil-treatment-enables-recovery-in-severe-copd-cases Lung Volume Reduction Coil Treatment Enables Recovery in Severe COPD Cases
The Efficacy of Lung Volume Reduction Coil Treatment in Patients with Severe Chronic Obstructive Pulmonary Disease (COPD) Type II Respiratory Failure
https://www.dovepress.com/the-efficacy-of-lung-volume-reduction-coil-treatment-in-patients-with–peer-reviewed-article-COPD https://www.ncbi.nlm.nih.gov/pubmed/32184585?dopt=Abstract The Efficacy of Lung Volume Reduction Coil Treatment in Patients with Severe Chronic Obstructive Pulmonary Disease (COPD) Type II Respiratory Failure. Related Articles The Efficacy of Lung Volume Reduction Coil Treatment in Patients with Severe Chronic Obstructive Pulmonary Disease (COPD) Type II Respiratory Failure. Int J Chron Obstruct Pulmon Dis. 2020;15:479-486 Authors: Yildiz […]
Inhalation therapy shows promise against pulmonary fibrosis in mice, rats
https://medicalxpress.com/news/2020-02-inhalation-therapy-pulmonary-fibrosis-mice.html Inhalation therapy shows promise against pulmonary fibrosis in mice, rats
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT04091360?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease Condition : COPD Interventions : Drug: Ensifentrine 100mcg; Drug: Ensifentrine 300mcg; Drug: Ensifentrine 1000mcg; Drug: Ensifentrine 3000mcg; Drug: Ensifentrine 6000mcg; Drug: Placebos Sponsors : Verona Pharma plc; Iqvia Pty Ltd Recruiting NCT04091360 Mon, 16 Sep 2019 12:00:00 EDT
Verona Pharma announces publication of Phase 2b clinical trial results for ensifentrine, a maintenance treatment for chronic obstructive pulmonary disease (COPD)
https://www.biospace.com/article/releases/verona-pharma-announces-publication-of-key-phase-2b-copd-data-in-respiratory-researchpaper-demonstrates-ensifentrine-s-potential-in-improving-lung-function-and-quality-of-life-symptoms Verona Pharma Announces Publication of Key Phase 2b COPD Data – Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms
New hope for COPD patients possible with in-home device
https://www.sciencedaily.com/releases/2020/02/200204163646.htm New hope for COPD patients possible with in-home device Date: February 4, 2020 Source: Mayo Clinic Summary: Researchers describe the benefits of in-home noninvasive ventilation therapy, which includes a type referred to as bilevel positive airway pressure, or BiPAP — for many patients with chronic obstructive pulmonary disease (COPD). The team identified a number […]
Verona Pharma Reports Positive Top-line Data in Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
https://www.globenewswire.com/news-release/2020/01/13/1969219/0/en/Verona-Pharma-Reports-Positive-Top-line-Data-in-4-Week-Phase-2b-COPD-Study-with-Nebulized-Ensifentrine-on-Top-of-Tiotropium-Therapy.html Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
Cancer drugs could potentially treat COPD
https://www.sciencedaily.com/releases/2020/01/200106103446.htm https://www.sheffield.ac.uk/news/nr/cancer-drugs-can-treat-copd-1.877500 Cancer drugs could potentially treat COPD Date: January 6, 2020 Source: University of Sheffield Summary: New research has shown the potential for clinically available cancer treatments to treat chronic obstructive pulmonary disease (COPD). Our research now shows that inhibitors of these cell signalling processes, or ErbB kinases, could have therapeutic potential in neutrophilic […]
The Safety and Feasibility of UMC119-06 Cell Therapy (Mesenchymal Stem Cells) in Subjects With Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT04206007?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease The Safety and Feasibility of UMC119-06 Cell Therapy in Subjects With Chronic Obstructive Pulmonary Disease Condition : Chronic Obstructive Pulmonary Disease Moderate Intervention : Biological: UMC119-06 Sponsor : Meridigen Biotech Co., Ltd. Not yet recruiting NCT04206007 Fri, 20 Dec 2019 12:00:00 EST
The key role of macrophage depolarization in the treatment of COPD with ergosterol
https://www.sciencedirect.com/science/article/pii/S1567576919322933?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/31874368?dopt=Abstract The key role of macrophage depolarization in the treatment of COPD with ergosterol both in vitro and in vivo. The key role of macrophage depolarization in the treatment of COPD with ergosterol both in vitro and in vivo. Int Immunopharmacol. 2019 Dec 20;79:106086 Authors: Sun X, Liu Y, Feng X, Li C, Li […]
Bu-Shen-Fang-Chuan formula (BSFCF) attenuates T-lymphocytes recruitment and improves pulmonary function in rat model of COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis
https://www.ncbi.nlm.nih.gov/pubmed/31864210?dopt=Abstract Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis. improved pulmonary function and attenuated CD8+ T-cells recruitment in rat model of COPD Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis. Biomed Pharmacother. 2019 Dec 17;123:109735 Authors: Li Q, Sun […]
Antiarrhythmic drug could also treat PAH, COPD
https://www.cardiovascularbusiness.com/topics/hypertension/antiarrhythmic-drug-could-also-treat-pah-copd Antiarrhythmic drug could also treat PAH, COPD
There’s now a life-changing treatment (Zephyr valve system) for COPD patients in Georgia
https://www.wsbtv.com/news/local/theres-new-life-changing-treatment-copd-patients-georgia/BLM4NI6DORHZLKZJJP7NASIV7M/ There’s now a life-changing treatment for COPD patients in Georgia
Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)
https://clinicaltrials.gov/ct2/show/NCT04047810?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD) Condition : Chronic Obstructive Pulmonary Disease Intervention : Biological: Mesenchymal Stem Cells Sponsor : Mayo Clinic Not yet recruiting NCT04047810 Wed, 07 Aug 2019 12:00:00 EDT
Oral formulation angiotensin-(1-7) therapy attenuates pulmonary and systemics damage in mice with emphysema
https://www.sciencedirect.com/science/article/pii/S0171298519302086?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/31837773?dopt=Abstract Oral formulation angiotensin-(1-7) therapy attenuates pulmonary and systemics damage in mice with emphysema induced by elastase. Related Articles Oral formulation angiotensin-(1-7) therapy attenuates pulmonary and systemics damage in mice with emphysema induced by elastase. Immunobiology. 2019 Dec 04;: Authors: Bastos AC, Magalhães GS, Gregório JF, Matos NA, Motta-Santos D, Bezerra FS, Santos RAS, […]
Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations: possibly a target for future therapeutics
https://onlinelibrary.wiley.com/doi/full/10.1002/kjm2.12147 https://www.ncbi.nlm.nih.gov/pubmed/31782610?dopt=Abstract Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations. Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations. Kaohsiung J Med Sci. 2019 Nov 29;: Authors: Sun Z, Zhu QL, Shen Y, Yan T, Zhou X Abstract Increasing evidence has indicated the intimate relationship between […]
Effectiveness of Xin Jia Xuan Bai Cheng Qi Decoction in treating acute exacerbation of chronic obstructive pulmonary disease: study protocol
https://bmjopen.bmj.com/content/9/11/e030249 https://www.ncbi.nlm.nih.gov/pubmed/31784433?dopt=Abstract Effectiveness of Xin Jia Xuan Bai Cheng Qi Decoction in treating acute exacerbation of chronic obstructive pulmonary disease: study protocol for a multicentre, randomised, controlled trial. Related Articles Effectiveness of Xin Jia Xuan Bai Cheng Qi Decoction in treating acute exacerbation of chronic obstructive pulmonary disease: study protocol for a multicentre, randomised, controlled […]
Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD
https://www.dovepress.com/dual-role-for-a-mek-inhibitor-as-a-modulator-of-inflammation-and-host–peer-reviewed-article-COPD https://www.ncbi.nlm.nih.gov/pubmed/32063702?dopt=Abstract Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD. Related Articles Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:2611-2624 Authors: Kurian […]
Role of melatonin as an SIRT1 enhancer in chronic obstructive pulmonary disease induced by cigarette smoke
https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.14816 https://www.ncbi.nlm.nih.gov/pubmed/31762195?dopt=Abstract Role of melatonin as an SIRT1 enhancer in chronic obstructive pulmonary disease induced by cigarette smoke. Related Articles Role of melatonin as an SIRT1 enhancer in chronic obstructive pulmonary disease induced by cigarette smoke. J Cell Mol Med. 2019 Nov 25;: Authors: Shin NR, Ko JW, Kim JC, Park G, Kim SH, Kim […]
LABAs and p38MAPK Inhibitors Reverse the Corticosteroid-Insensitivity of IL-8 in Airway Smooth Muscle Cells of COPD
https://www.mdpi.com/2077-0383/8/12/2058 https://www.ncbi.nlm.nih.gov/pubmed/31766770?dopt=Abstract LABAs and p38MAPK Inhibitors Reverse the Corticosteroid-Insensitivity of IL-8 in Airway Smooth Muscle Cells of COPD. Related Articles LABAs and p38MAPK Inhibitors Reverse the Corticosteroid-Insensitivity of IL-8 in Airway Smooth Muscle Cells of COPD. J Clin Med. 2019 Nov 22;8(12): Authors: Knobloch J, Jungck D, Kronsbein J, Stoelben E, Ito K, Koch A […]
Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art [Review]
https://www.sciencedirect.com/science/article/pii/S2531043719302089?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/31740261?dopt=Abstract “Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art.” Related Articles “Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art.” Pulmonology. 2019 Nov 15;: Authors: Corlateanu A, Mendez Y, Wang Y, Garnica RJA, Botnaru V, Siafakas N Abstract Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous and multisystemic disease with progressive increasing morbidity and mortality. […]
New Research Gives Hope for Slowing Progression and Mortality of Chronic Obstructive Pulmonary Disease (COPD)
https://www.copdfoundation.org/About-Us/Press-Room/Press-Releases/Article/1515/New-Research-Gives-Hope-for-Slowing-Progression-and-Mortality-of-Fourth-Leading.aspx New Research Gives Hope for Slowing Progression and Mortality of Chronic Obstructive Pulmonary Disease (COPD)
Acumapimod (BCT197) to Treat Acute Exacerbations of COPD
https://www.tandfonline.com/doi/abs/10.1080/15412555.2019.1682535?journalCode=icop20 https://www.ncbi.nlm.nih.gov/pubmed/31682162?dopt=Abstract Phase II Study of Single/Repeated Doses of Acumapimod (BCT197) to Treat Acute Exacerbations of COPD. Phase II Study of Single/Repeated Doses of Acumapimod (BCT197) to Treat Acute Exacerbations of COPD. COPD. 2019 Nov 04;:1-10 Authors: Strâmbu IR, Kobalava ZD, Magnusson BP, MacKinnon A, Parkin JM Abstract Mitogen-activated protein kinase p38 is a key […]
COPD Foundation: COPD Awareness Month is Here!
https://www.copdfoundation.org/About-Us/Press-Room/Press-Releases/Article/1510/COPD-Awareness-Month-is-Here.aspx COPD Awareness Month is Here!
Oscillating Vest Keeps COPD Patients Out of Hospital: Exacerbations reduced with technology initially designed for use in CF
https://www.medpagetoday.com/meetingcoverage/chest/82898 Oscillating Vest Keeps COPD Patients Out of Hospital Exacerbations reduced with technology initially designed for use in CF
Temple AIRFLOW-3 trial offers new approach to treating COPD
https://6abc.com/health/temple-airflow-3-trial-offers-new-approach-to-treating-copd/5638840/
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial for Ensifentrine in moderate-to-severe COPD
https://www.biospace.com/article/releases/verona-pharma-completes-enrollment-in-phase-2b-clinical-trial-with-nebulized-ensifentrine-in-moderate-to-severe-copdresults-to-inform-development-plan-and-dose-selection-for-phase-3/ Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPDResults to Inform Development Plan and Dose Selection for Phase 3
Bayer Will Invest $30M in Joint Research Lab for COPD, Other Chronic Lung Diseases
Bayer Will Invest $30M in Joint Research Lab for Chronic Lung Diseases Bayer Will Invest $30M in Joint Research Lab for COPD, Other Chronic Lung Diseases
Inhibitors of ErbB kinases have therapeutic potential in neutrophilic inflammatory diseases, including chronic obstructive pulmonary disease (COPD)
https://elifesciences.org/articles/50990 Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation Inhibitors of ErbB kinases have therapeutic potential in neutrophilic inflammatory diseases, including chronic obstructive pulmonary disease (COPD)
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine (RPL554) in COPD at CHEST 2019
http://www.globenewswire.com/news-release/2019/10/15/1929421/0/en/Verona-Pharma-to-Present-Phase-2-Symptom-Data-with-Ensifentrine-in-COPD-at-CHEST-2019.html Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
Airway pharmacology: treatment options and algorithms to treat patients with chronic obstructive pulmonary disease
https://pubmed.ncbi.nlm.nih.gov/31737347-airway-pharmacology-treatment-options-and-algorithms-to-treat-patients-with-chronic-obstructive-pulmonary-disease/?dopt=Abstract http://jtd.amegroups.com/article/view/32743/22939 https://www.ncbi.nlm.nih.gov/pubmed/31737347?dopt=Abstract Airway pharmacology: treatment options and algorithms to treat patients with chronic obstructive pulmonary disease. Related Articles Airway pharmacology: treatment options and algorithms to treat patients with chronic obstructive pulmonary disease. J Thorac Dis. 2019 Oct;11(Suppl 17):S2200-S2209 Authors: Kerstjens HAM, Upham JW, Yang IA Abstract Pharmacological treatment of patients with chronic obstructive pulmonary […]
Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases
https://onlinelibrary.wiley.com/doi/abs/10.1002/wnan.1586 https://www.ncbi.nlm.nih.gov/pubmed/31602823 Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Oct 10:e1586. doi: 10.1002/wnan.1586. [Epub ahead of print] Abstract Respiratory illnesses are prevalent around the world, and inhalation-based therapies provide an attractive, noninvasive means of directly delivering therapeutic agents to their site of action to improve treatment […]
Lipids in COPD: A Target for Future Therapy? [PDF]
https://www.atsjournals.org/doi/pdf/10.1165/rcmb.2019-0338ED https://www.ncbi.nlm.nih.gov/pubmed/31577908?dopt=Abstract Lipids in COPD: A Target for Future Therapy? Lipids in COPD: A Target for Future Therapy? Am J Respir Cell Mol Biol. 2019 Oct 02;: Authors: Vlahos R PMID: 31577908 [PubMed – as supplied by publisher] PubMed:31577908 Vlahos R
Allyl isothiocyanate (AITC) may reverse the expression of MRP1 in COPD rats via the Notch1 signaling pathway
https://link.springer.com/article/10.1007%2Fs12272-019-01183-4 https://www.ncbi.nlm.nih.gov/pubmed/31571144?dopt=Abstract “targeting the Notch signaling pathway may present as an effective therapeutic strategy for COPD treatment” Allyl isothiocyanate may reverse the expression of MRP1 in COPD rats via the Notch1 signaling pathway. Allyl isothiocyanate may reverse the expression of MRP1 in COPD rats via the Notch1 signaling pathway. Arch Pharm Res. 2019 Sep 30;: […]
Therapeutic efficacy of the aqueous extract of the stem bark of Ximenia americana L. in the treatment of experimental COPD in rats
https://www.sciencedirect.com/science/article/pii/S037887411932728X?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/31577938?dopt=Abstract Phytochemical study, molecular docking, genotoxicity and therapeutic efficacy of the aqueous extract of the stem bark of Ximenia americana L. in the treatment of experimental COPD in rats. Phytochemical study, molecular docking, genotoxicity and therapeutic efficacy of the aqueous extract of the stem bark of Ximenia americana L. in the treatment of experimental […]
DT-0111: a novel drug-candidate for the treatment of COPD and chronic cough
hhttps://journals.sagepub.com/doi/10.1177/1753466619877960 ttps://www.ncbi.nlm.nih.gov/pubmed/31558105?dopt=Abstract DT-0111: a novel drug-candidate for the treatment of COPD and chronic cough. Related Articles DT-0111: a novel drug-candidate for the treatment of COPD and chronic cough. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619877960 Authors: Pelleg A, Xu F, Zhuang J, Undem B, Burnstock G Abstract BACKGROUND: Extracellular adenosine 5′-triphosphate (ATP) plays important mechanistic roles […]
AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients
https://www.globenewswire.com/news-release/2019/09/25/1920526/0/en/AzurRx-BioPharma-Announces-Positive-Results-from-Phase-2-Trial-with-MS1819-in-Cystic-Fibrosis-Patients.html AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients
AstraZeneca to present next wave of science in respiratory disease at ERS International Congress
https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-next-wave-of-science-in-respiratory-disease-at-ers-international-congress-25092019.html AstraZeneca to present next wave of science in respiratory disease at ERS International Congress
The Use of Benralizumab, an Interleukin-5 Receptor-α Monoclonal Antibody as Treatment of Acute Exacerbations of Airways Disease
https://clinicaltrials.gov/ct2/show/NCT04098718?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Acute Exacerbations Treated With BenRAlizumab (The ABRA Study) Conditions : Asthma; COPD Interventions : Drug: Benralizumab; Drug: Prednisolone Sponsor : University of Oxford Not yet recruiting NCT04098718 Mon, 23 Sep 2019 12:00:00 EDT
COPD: preclinical models and emerging therapeutic targets
https://www.tandfonline.com/doi/abs/10.1080/14728222.2019.1667976?journalCode=iett20 https://www.ncbi.nlm.nih.gov/pubmed/31512957?dopt=Abstract COPD: preclinical models and emerging therapeutic targets. COPD: preclinical models and emerging therapeutic targets. Expert Opin Ther Targets. 2019 Sep 12;: Authors: Barreiro E, Wang X, Tang J Abstract Introduction: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Preclinical models of COPD have recently been developed. In […]
Dissection of Pharmacological Mechanism of Chinese Herbal Medicine Yihuo Huatan Formula on Chronic Obstructive Pulmonary Disease
https://www.nature.com/articles/s41598-019-50064-9 https://www.ncbi.nlm.nih.gov/pubmed/31530860?dopt=Abstract Dissection of Pharmacological Mechanism of Chinese Herbal Medicine Yihuo Huatan Formula on Chronic Obstructive Pulmonary Disease: A Systems Pharmacology-Based Study. Dissection of Pharmacological Mechanism of Chinese Herbal Medicine Yihuo Huatan Formula on Chronic Obstructive Pulmonary Disease: A Systems Pharmacology-Based Study. Sci Rep. 2019 Sep 17;9(1):13431 Authors: Zhang XW, Liu W, Jiang HL, Mao […]
Carbocisteine inhibits the expression of Muc5b in COPD mouse model
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754527/ https://www.dovepress.com/carbocisteine-inhibits-the-expression-of-muc5b-in-copd-mouse-model-peer-reviewed-article-DDDT https://www.ncbi.nlm.nih.gov/pubmed/31571828?dopt=Abstract “carbocisteine attenuated Muc5b and Muc5ac secretion and restored Muc5b protein levels, which may improve mucus clearance in COPD” Carbocisteine inhibits the expression of Muc5b in COPD mouse model. Carbocisteine inhibits the expression of Muc5b in COPD mouse model. Drug Des Devel Ther. 2019;13:3259-3268 Authors: Song Y, Wang W, Xie Y, Xiang B, […]
Anti-viral immunity is impaired in COPD patients with frequent exacerbations
https://www.physiology.org/doi/abs/10.1152/ajplung.00253.2019 https://www.ncbi.nlm.nih.gov/pubmed/31513433?dopt=Abstract Anti-viral immunity is impaired in COPD patients with frequent exacerbations. Anti-viral immunity is impaired in COPD patients with frequent exacerbations. Am J Physiol Lung Cell Mol Physiol. 2019 Sep 12;: Authors: Singanayagam A, Loo SL, Calderazzo MA, Finney LJ, Trujillo Torralbo MB, Bakhsoliani E, Girkin J, Veerati PC, Pathinayake PS, Nichol KS, Reid […]
Curcumin ameliorates chronic obstructive pulmonary disease by modulating autophagy and endoplasmic reticulum stress through regulation of SIRT1 in a rat model
https://journals.sagepub.com/doi/10.1177/0300060519869459 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833429/ https://www.ncbi.nlm.nih.gov/pubmed/31510839?dopt=Abstract Curcumin ameliorates chronic obstructive pulmonary disease by modulating autophagy and endoplasmic reticulum stress through regulation of SIRT1 in a rat model. Related Articles Curcumin ameliorates chronic obstructive pulmonary disease by modulating autophagy and endoplasmic reticulum stress through regulation of SIRT1 in a rat model. J Int Med Res. 2019 Oct;47(10):4764-4774 Authors: Tang […]
Study to evaluate the impact of inhaled PT003 in moderate to severe COPD patients
https://clinicaltrials.gov/ct2/show/NCT04087590?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient Condition : Copd Intervention : Drug: Formoterol-glycopyrronium co suspension (PT003) Sponsors : University Hospital, Lille; AstraZeneca Not yet recruiting NCT04087590 Thu, 12 Sep 2019 12:00:00 EDT
miRNA‑101‑3p.1 facilitates COPD progression by activating the EGFR/PI3K/AKT signaling pathway
https://www.spandidos-publications.com/10.3892/mmr.2019.10657 https://www.ncbi.nlm.nih.gov/pubmed/31545413?dopt=Abstract miRNA‑101‑3p.1 as an independent diagnostic biomarker aggravates chronic obstructive pulmonary disease via activation of the EGFR/PI3K/AKT signaling pathway. miRNA‑101‑3p.1 as an independent diagnostic biomarker aggravates chronic obstructive pulmonary disease via activation of the EGFR/PI3K/AKT signaling pathway. Mol Med Rep. 2019 Sep 09;: Authors: Chen S, Zhang Z, Chen L, Zhang J Abstract Exploring […]
Therapeutic potential of BLT1 antagonist for COPD: involvement of inducing autophagy and ameliorating inflammation
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732561/ https://www.dovepress.com/therapeutic-potential-of-blt1-antagonist-for-copd-involvement-of-induc-peer-reviewed-article-DDDT https://www.ncbi.nlm.nih.gov/pubmed/31564828?dopt=Abstract Therapeutic potential of BLT1 antagonist for COPD: involvement of inducing autophagy and ameliorating inflammation. Related Articles Therapeutic potential of BLT1 antagonist for COPD: involvement of inducing autophagy and ameliorating inflammation. Drug Des Devel Ther. 2019;13:3105-3116 Authors: Zhang L, Huang J, Dong R, Feng Y, Zhou M Abstract Purpose: Leukotriene B4 (LTB4) is […]
Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies
https://www.karger.com/Article/Abstract/502261 https://www.ncbi.nlm.nih.gov/pubmed/31480060?dopt=Abstract Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies. Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies. Respiration. 2019 Sep 03;:1-16 Authors: van Eeden SF, Hogg JC Abstract Chronic obstructive pulmonary disease (COPD) is caused by the chronic inhalation of toxic particles and gases that are primarily but […]
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD
https://www.ncbi.nlm.nih.gov/pubmed/31474120?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/31474120?dopt=Abstract Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Related Articles Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019 Sep 01;:1-7 Authors: Cazzola M, Calzetta L, Rogliani P, Matera MG Abstract Introduction: A compound that simultaneously inhibits PDE3 and PDE4 should increase airway […]
Pharmacological treatment and current controversies in COPD
https://f1000research.com/articles/8-1533/v1 https://www.ncbi.nlm.nih.gov/pubmed/31508197?dopt=Abstract Pharmacological treatment and current controversies in COPD. Pharmacological treatment and current controversies in COPD. F1000Res. 2019;8: Authors: Cazzola M, Rogliani P, Stolz D, Matera MG Abstract Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and […]
Efficacy and safety of inhaled alpha-1-antitrypsin in severe COPD patients with alpha-1-antitrypsin deficiency
https://erj.ersjournals.com/content/early/2019/08/14/13993003.00673-2019 https://www.ncbi.nlm.nih.gov/pubmed/31467115?dopt=Abstract Efficacy and safety of inhaled alpha-1-antitrypsin in patients with severe alpha-1-antitrypsin deficiency and frequent exacerbations of Chronic Obstructive Pulmonary Disease. Related Articles Efficacy and safety of inhaled alpha-1-antitrypsin in patients with severe alpha-1-antitrypsin deficiency and frequent exacerbations of Chronic Obstructive Pulmonary Disease. Eur Respir J. 2019 Aug 29;: Authors: Stolk J, Tov N, […]
PT010 Phase III ETHOS Trial Met Its Primary Endpoint in COPD
https://www.biospace.com/article/pt010-phase-iii-ethos-trial-met-its-primary-endpoint-in-copd/ PT010 Phase III ETHOS Trial Met Its Primary Endpoint in COPD
CARM1 contributes to airway repair and regeneration by regulating airway epithelial cell senescence
https://www.physiology.org/doi/abs/10.1152/ajplung.00441.2018 https://www.ncbi.nlm.nih.gov/pubmed/31461302?dopt=Abstract CARM1 regulates senescence during airway epithelial cell injury in COPD pathogenesis. CARM1 regulates senescence during airway epithelial cell injury in COPD pathogenesis. Am J Physiol Lung Cell Mol Physiol. 2019 Aug 28;: Authors: Sarker RSJ, Conlon TM, Morrone C, Srivastava B, Konyalilar N, Verleden SE, Bayram H, Fehrenbach H, Yildirim AÖ Abstract Chronic […]
Wharton’s jelly-derived mesenchymal stem cells show pulmonary regenerative effects in COPD mouse model
https://www.sciencedirect.com/science/article/pii/S2352320419300227?via%3Dihub https://www.ncbi.nlm.nih.gov/pubmed/31489344?dopt=Abstract Effects of Wharton’s jelly-derived mesenchymal stem cells on chronic obstructive pulmonary disease. Related Articles Effects of Wharton’s jelly-derived mesenchymal stem cells on chronic obstructive pulmonary disease. Regen Ther. 2019 Dec;11:207-211 Authors: Cho JW, Park KS, Bae JY Abstract Objectives: Chronic obstructive pulmonary disease (COPD) is a fatal disease that shortens one’s life expectancy […]
Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
https://www.dovepress.com/mepolizumab-in-the-treatment-of-eosinophilic-chronic-obstructive-pulmo-peer-reviewed-fulltext-article-COPD https://www.ncbi.nlm.nih.gov/pubmed/31496677?dopt=Abstract Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:1779-1787 Authors: Mkorombindo T, Dransfield MT Abstract Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary disease continue to suffer acute exacerbations. It is […]
Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects
https://clinicaltrials.gov/ct2/show/NCT04032535 Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects (CHF6523)
Personalized medicine for patients with COPD: where are we?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636434/ https://www.ncbi.nlm.nih.gov/pubmed/31371934?dopt=Abstract Personalized medicine for patients with COPD: where are we? Related Articles Personalized medicine for patients with COPD: where are we? Int J Chron Obstruct Pulmon Dis. 2019;14:1465-1484 Authors: Franssen FM, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, Maxheim M, Roessler FK, Spruit MA, Vogelmeier CF, Wouters EF, Schmeck B Abstract […]
Photobiomodulation in Individuals With Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT04010084?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Photobiomodulation in Individuals With Chronic Obstructive Pulmonary Disease Condition : Chronic Obstructive Pulmonary Disease Interventions : Radiation: Low level laser therapy; Procedure: Placebo group Sponsor : University of Nove de Julho Not yet recruiting NCT04010084 Mon, 08 Jul 2019 12:00:00 EDT Effectiveness of Photobiomodulation in Individuals With Chronic Obstructive Pulmonary Disease – Randomized Clinical Trial
Ergosterol attenuates cigarette smoke extract-induced COPD by modulating inflammation, oxidative stress and apoptosis in vitro and in vivo
http://www.clinsci.org/content/early/2019/07/03/CS20190331 https://www.ncbi.nlm.nih.gov/pubmed/31270147?dopt=Abstract Ergosterol attenuates cigarette smoke extract-induced COPD by modulating inflammation, oxidative stress and apoptosis in vitro and in vivo. Related Articles Ergosterol attenuates cigarette smoke extract-induced COPD by modulating inflammation, oxidative stress and apoptosis in vitro and in vivo. Clin Sci (Lond). 2019 Jul 03;: Authors: Sun X, Feng X, Zheng D, Li A, […]
Chemokines in COPD: From Implication to Therapeutic Use
https://www.mdpi.com/1422-0067/20/11/2785 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600384/ https://www.ncbi.nlm.nih.gov/pubmed/31174392?dopt=Abstract Chemokines in COPD: From Implication to Therapeutic Use. Related Articles Chemokines in COPD: From Implication to Therapeutic Use. Int J Mol Sci. 2019 Jun 06;20(11): Authors: Henrot P, Prevel R, Berger P, Dupin I Abstract : Chronic Obstructive Pulmonary Disease (COPD) represents the 3rd leading cause of death in the world. The […]
12-month randomised controlled trial of ginseng extract for moderate COPD: no significant differences between ginseng and placebo
https://thorax.bmj.com/content/74/6/539 https://www.ncbi.nlm.nih.gov/pubmed/30940771?dopt=Abstract 12-month randomised controlled trial of ginseng extract for moderate COPD. Related Articles 12-month randomised controlled trial of ginseng extract for moderate COPD. Thorax. 2019 06;74(6):539-545 Authors: Shergis JL, Thien F, Worsnop CJ, Lin L, Zhang AL, Wu L, Chen Y, Xu Y, Langton D, Da Costa C, Fong H, Wu D, Story D, […]
MicroRNAs in COPD: small molecules with big potential
https://erj.ersjournals.com/content/53/4/1900515 https://www.ncbi.nlm.nih.gov/pubmed/31023868?dopt=Abstract MicroRNAs in COPD: small molecules with big potential. Related Articles MicroRNAs in COPD: small molecules with big potential. Eur Respir J. 2019 Apr;53(4): Authors: Hobbs BD, Tantisira KG PMID: 31023868 [PubMed – indexed for MEDLINE] PubMed:31023868 Hobbs BD, Tantisira KG
Circassia Pharma Receives 2nd FDA Approval for COPD Treatment in 2 Weeks
https://www.biospace.com/article/circassia-pharma-receives-2nd-fda-approval-for-copd-treatment-in-2-weeks/
Macrolides for treatment of chronic obstructive pulmonary disease
https://journals.lww.com/cmj/Citation/publishahead/Macrolides_for_treatment_of_chronic_obstructive.99830.aspx https://www.ncbi.nlm.nih.gov/pubmed/30973449?dopt=Abstract Macrolides for treatment of chronic obstructive pulmonary disease. Macrolides for treatment of chronic obstructive pulmonary disease. Chin Med J (Engl). 2019 Apr 03;: Authors: Sun XJ, He ZY PMID: 30973449 [PubMed – as supplied by publisher] PubMed:30973449 Sun XJ, He ZY
The Effectiveness of Bottle-PEP in Chronic Obstructive Pulmonary Disease
https://clinicaltrials.gov/ct2/show/NCT03900195?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 The Effectiveness of Bottle-PEP in Chronic Obstructive Pulmonary Disease Condition : Chronic Obstructive Pulmonary Disease Intervention : Other: BottlePEP Sponsor : Marmara University Recruiting NCT03900195 Tue, 02 Apr 2019 12:00:00 EDT Phase N/A
